Does a Ketogenic Diet As an Adjuvant Therapy for Drug Treatment Enhance Chemotherapy Sensitivity and Reduce Target Lesions in Patients with Locally Recurrent or Metastatic Her-2-negative Breast Cancer? Study Protocol for a Randomized Controlled Trial

Overview

Journal Trials

Publisher Biomed Central

Specialties General Medicine
Pharmacology

Date 2020 Jun 7

PMID 32503654

Citations 9

Authors

Yan Wang

Ming-Xi Jing

Lei Jiang

Yu-Feng Jia

E Ying

Hui Cao

Xiang-Yu Guo

Tao Sun

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have indicated that a ketogenic diet can be used as an adjuvant therapy to enhance sensitivity to chemotherapy and radiotherapy in cancer patients. However, there are no sufficient data and no consistent international treatment guidelines supporting a ketogenic diet as an adjuvant therapy for metastatic breast cancer. Therefore, this trial was designed to observe whether irinotecan with a ketogenic diet can promote sensitivity to chemotherapy and remit target lesions in locally recurrent or metastatic Her-2-negative breast cancer patients.

Methods/design: This trial aims to recruit 518 women with locally recurrent or metastatic breast cancer admitted to the Liaoning Cancer Hospital and Institute (Shenyang, China) in northeast China. All patients will be randomly assigned into the combined intervention group (n = 259) or the control group (n = 259), followed by treatment with irinotecan + ketogenic diet or irinotecan + normal diet, respectively. The primary endpoints are sensitivity to irinotecan and the objective response rate of target lesions; the secondary endpoints include quality of life scores (EORTC QLQ-C30), progression-free survival, overall survival time, incidence of adverse events, and cost-effectiveness. The endpoints will be evaluated at baseline (before drug administration), during treatment, 4 weeks after treatment completion, and every 3months (beginning 2 months after treatment completion).

Discussion: This trial attempts to investigate whether irinotecan treatment with a ketogenic diet for locally recurrent or metastatic breast cancer among women in northeast China can enhance the disease's sensitivity to chemotherapy and reduce target lesions.

Trial Registration: Chinese Clinical Trial Registry, ID: ChiCTR1900024597. Registered on 18 July 2019. Protocol Version: 1.1, 24 February 2017.

Citing Articles

Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study.

Kiryttopoulos A, Evangeliou A, Katsanika I, Boukovinas I, Foroglou N, Zountsas B Front Nutr. 2025; 11:1489812.

PMID: 40041752 PMC: 11876051. DOI: 10.3389/fnut.2024.1489812.

Ketogenic diet and cancer: multidimensional exploration and research.

Wan S, Zhou X, Xie F, Zhou F, Zhang L Sci China Life Sci. 2025; .

PMID: 39821829 DOI: 10.1007/s11427-023-2637-2.

Systematic Review and Clinical Insights: The Role of the Ketogenic Diet in Managing Glioblastoma in Cancer Neuroscience.

Valerio J, Borro M, Proietti E, Pisciotta L, Olarinde I, Fernandez Gomez M J Pers Med. 2024; 14(9).

PMID: 39338183 PMC: 11433106. DOI: 10.3390/jpm14090929.

Targeting fatty acid oxidation enhances response to HER2-targeted therapy.

Nandi I, Ji L, Smith H, Avizonis D, Papavasiliou V, Lavoie C Nat Commun. 2024; 15(1):6587.

PMID: 39097623 PMC: 11297952. DOI: 10.1038/s41467-024-50998-3.

Dietary Influence on Drug Efficacy: A Comprehensive Review of Ketogenic Diet-Pharmacotherapy Interactions.

Marinescu S, Apetroaei M, Nedea M, Arsene A, Velescu B, Hincu S Nutrients. 2024; 16(8).

PMID: 38674903 PMC: 11054576. DOI: 10.3390/nu16081213.

References

Frommelt L, Bielohuby M, Stoehr B, Menhofer D, Bidlingmaier M, Kienzle E . Effects of low-carbohydrate, high-fat diets on apparent digestibility of minerals and trace elements in rats. Nutrition. 2014; 30(7-8):869-75. DOI: 10.1016/j.nut.2013.11.017. View

Perez E, Hillman D, Mailliard J, Ingle J, Ryan J, Fitch T . Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004; 22(14):2849-55. DOI: 10.1200/JCO.2004.10.047. View

Branca J, Pacini S, Ruggiero M . Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. Anticancer Res. 2015; 35(10):5525-32. View

Meng X, Song S . [Diagnosis and treatment of osteoblastic metastasis in patients with breast cancer]. Zhonghua Zhong Liu Za Zhi. 2018; 40(6):401-405. DOI: 10.3760/cma.j.issn.0253-3766.2018.06.001. View

Guo W, Hao B, Luo N, Ruan D, Guo X, Chen H . Early re-staging and molecular subtype shift surveillance of locally recurrent or metastatic breast cancer: A new PET/CT integrated precise algorithm. Cancer Lett. 2018; 418:221-229. DOI: 10.1016/j.canlet.2018.01.019. View

Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794-803. DOI: 10.1200/JCO.2005.04.937. View

Little R, DAgostino R, Cohen M, Dickersin K, Emerson S, Farrar J . The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012; 367(14):1355-60. PMC: 3771340. DOI: 10.1056/NEJMsr1203730. View

OShaughnessy J . Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005; 10 Suppl 3:20-9. DOI: 10.1634/theoncologist.10-90003-20. View

Dueck A, Mendoza T, Mitchell S, Reeve B, Castro K, Rogak L . Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015; 1(8):1051-9. PMC: 4857599. DOI: 10.1001/jamaoncol.2015.2639. View

10.

Chan A, Tetzlaff J, Altman D, Laupacis A, Gotzsche P, Krleza-Jeric K . SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158(3):200-7. PMC: 5114123. DOI: 10.7326/0003-4819-158-3-201302050-00583. View

11.

Iyikesici M, Slocum A, Slocum A, Berkarda F, Kalamian M, Seyfried T . Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Cureus. 2017; 9(7):e1445. PMC: 5589510. DOI: 10.7759/cureus.1445. View

12.

Crozier J, Advani P, Laplant B, Hobday T, Jaslowski A, Moreno-Aspitia A . N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer. 2015; 16(1):23-30. PMC: 4698217. DOI: 10.1016/j.clbc.2015.08.002. View

13.

Shigeoka Y, Itoh K, Igarashi T, Ishizawa K, Saeki T, Fujii H . Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol. 2001; 31(8):370-4. DOI: 10.1093/jjco/hye082. View

14.

Klement R, Champ C, Otto C, Kammerer U . Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis. PLoS One. 2016; 11(5):e0155050. PMC: 4861343. DOI: 10.1371/journal.pone.0155050. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Awada A, Garcia A, Chan S, Jerusalem G, Coleman R, Huizing M . Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013; 14(12):1216-25. DOI: 10.1016/S1470-2045(13)70429-7. View

17.

Smyl C . Ketogenic Diet and Cancer-a Perspective. Recent Results Cancer Res. 2016; 207:233-40. DOI: 10.1007/978-3-319-42118-6_11. View

18.

Morscher R, Aminzadeh-Gohari S, Feichtinger R, Mayr J, Lang R, Neureiter D . Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model. PLoS One. 2015; 10(6):e0129802. PMC: 4459995. DOI: 10.1371/journal.pone.0129802. View

19.

Poff A, Ari C, Seyfried T, DAgostino D . The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013; 8(6):e65522. PMC: 3673985. DOI: 10.1371/journal.pone.0065522. View

20.

Bevers T, Helvie M, Bonaccio E, Calhoun K, Daly M, Farrar W . Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(11):1362-1389. DOI: 10.6004/jnccn.2018.0083. View